Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
O6-benzylguanine plus carmustine in newly diagnosed glioblastoma
NCT00046878Phase 2Withdrawn
- Sponsor
- Duke University
- Modality
- Metabolically Activated Prodrugs
01
Overview
Phase 2, open-label, single-arm trial of 6-benzylguanine in glioblastoma multiforme (GBM), sponsored by Duke University. Primary endpoints: Antitumor Activity and Toxicity. Status: withdrawn.
02
Drugs
6-benzylguanine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00046878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046878.